Last update 21 Nov 2024

Risdiplam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Risdiplam (JAN/USAN/INN)
+ [6]
Target
Mechanism
SMN2 modulators(Survival motor neuron protein modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (07 Aug 2020),
RegulationPRIME (EU), Accelerated assessment (EU), Special Review Project (CN), Orphan Drug (EU), Priority Review (AU), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC22H23N7O
InChIKeyASKZRYGFUPSJPN-UHFFFAOYSA-N
CAS Registry1825352-65-5

External Link

KEGGWikiATCDrug Bank
D11406Risdiplam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Spinal Muscular Atrophy
CA
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Spinal Muscular AtrophyPhase 3
GB
02 Jun 2022
Spinal Muscular Atrophies of ChildhoodPhase 2
BR
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
HR
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
IT
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
ES
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
US
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
FR
27 Sep 2016
Spinal Muscular Atrophies of ChildhoodPhase 2
US
27 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
23
tsrhhlbnfm(yfylyxmztu) = All of the children treated with Evrysdi who had three or more SMN2 copies (n=18), achieved standing and walking (100%). vvrizpcqna (tjhzetcvmf )
Met
Positive
14 Oct 2024
Not Applicable
-
tikdvrqnvu(ajhktwsecf) = vxnhxjrsru lpeubbkpeb (rifyokbujp )
-
28 Jun 2024
Not Applicable
-
(ltkcuomycb) = mucjyukgjx vpcqqodwxt (jzsunwlwas )
Positive
14 Jun 2024
Phase 2
Spinal Muscular Atrophy
ulnar CMAP amplitude
26
cylmrpccqm(hteeqizehb) = nskwwovbhx vtxzyuejoi (qvagpnssht )
Positive
09 Apr 2024
Phase 3
Spinal Muscular Atrophy
SMN2 copies | ulnar CMAP amplitude
26
(irrqxphlif) = jdmnvoshjs ezfuydhtow (ookfpprcdi )
Positive
03 Mar 2024
Not Applicable
-
ruozphqkmu(uqopdeouae) = wqixxobngn bxiggrasah (rgukudusri )
Positive
03 Mar 2024
ruozphqkmu(uqopdeouae) = wgczgvqqlc bxiggrasah (rgukudusri )
Not Applicable
-
wxcoqwjvnn(uumuiwskpy) = One infant had a single overdose 10x intended dosing without related sequelae ihsywxozzw (qhslxhsouo )
Positive
03 Mar 2024
Not Applicable
SMN2 gene transcription
56
udgjfylqho(vsswdydrwu) = 6 patients had transient diarrhea, but we observed no significant side effects lktrvprruc (ezlatdaurs )
Positive
28 Jun 2023
Not Applicable
-
dllkklgfge(ttrfsvuxkv) = gjhwjjszvj qyhmnhjuxo (vtuvmygxpz, 22)
-
19 Mar 2023
Not Applicable
155
(isjsbpioax) = The most frequently reported adverse events were diarrhea (n = 10; 6.5%), pyrexia (n = 7; 4.5%), and upper respiratory tract infection (n = 5; 3.2%). The most frequently reported serious adverse event was pneumonia (n = 3; 1.9%). No deaths were reported. dmjengrbed (kjxjehftvf )
Positive
14 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free